Core Insights - The U.S. Food and Drug Administration (FDA) has extended its review of Ascendis Pharma's therapy aimed at treating children with a rare genetic disorder that leads to dwarfism [1] Company Summary - Ascendis Pharma is currently awaiting the FDA's decision on its therapy for a specific genetic disorder affecting children [1]